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Peripartum cardiomyopathy (PPCM) is a rare but serious
form of cardiac failure affecting women in the last months
of pregnancy or early puerperium. Clinical presentation of
PPCM is similar to that of systolic heart failure from any
cause, and it can sometimes be complicated by a high
incidence of thromboembolism. Prior to the availability of
echocardiography, diagnosis was based only on clinical
findings. Recently, inclusion of echocardiography has made
diagnosis of PPCM easier and more accurate. Its etiopatho-
genesis is still poorly understood, but recent evidence
supports inflammation, viral infection and autoimmunity as
the leading causative hypotheses. Prompt recognition with
institution of intensive treatment by a multidisciplinary team
is a prerequisite for improved outcome. Conventional
treatment consists of diuretics, blockers, vasodilators, and β
sometimes digoxin and anticoagulants, usually in combination.
In resistant cases, newer therapeutic modalities such as
immunomodulation, immunoglobulin and immunosuppres-
sion may be considered. Cardiac transplantation may be
necessary in patients not responding to conventional and
newer therapeutic strategies. The role of the anesthesiologist
is important in perioperative and intensive care management.
Prognosis is highly related to reversal of ventricular
dysfunction. Compared to historically higher mortality rates,
recent reports describe better outcome, probably because of
advances in medical care. Based on current information,
future pregnancy is usually not recommended in patients who
fail to recover heart function. This article aims to provide a
comprehensive updated review of PPCM covering etiopatho-
geneses, clinical presentation and diagnosis, as well as phar-
macological, perioperative and intensive care management
and prognosis, while stressing areas that require further
research.
Key Words: Cardiomyopathy, peripartum, obstetrics, compli-
cations, anesthesia
INTRODUCTION
Peripartum cardiomyopathy (PPCM) is a
devastating form of cardiac failure affecting
women mainly in their last months of pregnancy
or early puerperium and often complicating their
obstetrics as well as anesthetic management. Setting
aside several historical expressions,
1-5 “peripartum
cardiomyopathy” is now the term widely used to
describe this clinical situation.
1-3,6,7 In 1971,
Demakis et al. first defined PPCM with three
distinctive criteria (Table 1).
1,2 The strict time limit
used in their diagnostic criteria was intended to
exclude congenital and acquired causes of heart
failure that usually manifest by the second
trimester.
1,8 Even so, the occurrence of PPCM has
been overestimated
6,9,10 As a result, the PPCM
workshop committee recommended the inclusion
of echocardiographic features of left ventricular
dysfunction to redefine PPCM.
11 Specific echocar-
diographic diagnostic criteria have been proposed
(Table 2),
12 and their addition has resulted in
easier differentiation between PPCM and other
causes of cardiac failure.
9,13
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Table 1. Diagnostic Criteria for PPCM
Diagnostic criteria for PPCM:
Development of heart failure within last month of
pregnancy or six month postpartum.
Absence of any identifiable cause for heart failure.
Absence of any recognizable heart disease before
last month of pregnancy.
Review ArticleTable 2. Additional Echocardiographic Diagnostic
Criteria
Demonstrable echocardiographic criteria of left ventri-
cular dysfunction:
Ejection fraction < 45%
Left ventricular fractional shortening < 30%
Left ventricular end-diastolic dimension > 2.7 cm/m
2
body surface area.
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INCIDENCE
The incidence of PPCM varies worldwide.
14 The
first report of cardiac failure in pregnancy was
made in 1849 by Ritchie,
15 and it was commonly
described as cardiomyopathy in the 1930s
4,16
Reported incidence of PPCM in non-African
countries ranges between 1 : 3,000 to 1 : 15,000 live
births.
2,3,6,7,9,14,17 In South Africa, the reported
incidence is higher (1 : 1,000 live births).
18 A much
higher incidence of 1 : 300 live births has been
reported from Haiti,
19 and an extremely high rate
of 1% has been described in Nigeria.
20 Higher
rates in developing countries may be due to
variations in local cultural as well as puerperal
practices, ecological factors, environmental in-
fluence, diagnostic criteria and reporting pattern
used.
3,20-23 Diagnosis based only on clinical
features has also overestimated the incidence.
1,6,9,10
A report from the United States of America (USA)
revealed that PPCM is misdiagnosed in 50 - 75%
cases.
6,13,24 PPCM is estimated to make up less
than 1% of pregnant mother-associated cardiovas-
cular abnormalities.
3,25 Overall, recent reports
from various parts of the World show an
incidence of 1 in 1,485 to 4,000 live births
3,5,14,17,21,
26-28 and the trend is increasing.
5,11,28
RISK FACTORS
Common reported risk factors for PPCM are
advanced maternal age, multiparity, multiple
gestations, black race, obesity, malnutrition, gesta-
tional hypertension, preeclampsia, poor antenatal
care, breast feeding, cesarean section, alcohol,
cocaine and tobacco abuse, low socioeconomic
condition and family history.
1-11,13,14,17-35 PPCM has
been reported mostly in women older than 30
years,
1-3,8,14,17,18,29,32,34,36,37 but it may occur in
various age groups.
2,13,27,29,35,36,38-43,44 Though PPCM
has been reported in primigravida,
1,2,8,18,19,27,29-31,
38-42,45 it is found to occur more commonly with
multiparity.
1-3,6,8,14,17,19,24,25,28,29,34 in the USA the
majority of afflicted Americans are of African
Americans,
1-4,7,14,17,20,24,25,35 though, Asian (Korean,
Japanese, Chinese and Indians), Hispanic and
Caucasians mothers have also been affected with
PPCM.
2,3,9,17,25,29,39 Twin pregnancy appears to
cause a higher risk of developing PPCM.
1-9,21-23,
26-29 The reason for the association of PPCM with
higher age, parity, multiple gestation and black
race is not fully understood.
5 Recently, it has
occurred increasingly in younger, primigravida
and white mothers.
8,9,14,19,21,25,27,29,38,44,46 Higher age
and parity are also becoming less distinct
predisposing factors for the development of
PPCM.
19,31,34,35
Reports of PPCM are available from tropical
and subtropical regions,
4,18,20 and the increased
heat, humidity, high salt and fluid intake and the
associated hypertension, local puerperal practices
and lack of modern diagnostic facilities may be
responsible for the observed extremely high
incidence
3,14,20,21,23,26 Typical etiological nature
points towards hypertensive heart failure caused
by fluid overload rather than a true variety of
PPCM.
14 Preeclampsia and hypertension have
been associated with a significant number of
PPCM cases.
1-6,9,14,16-18,20,25,27,29,35,44 Many authors
even report it as a variety of hypertensive heart
failure.
4,6,19,46 However, preeclampsia alone rarely
leads to heart failure in healthy women.
6,17,29
Absence of vascular changes and disappearance of
hypertension and preeclampsia before the onset of
heart failure indicate that hypertension likely is
merely associated with and aggravates PPCM,
rather than playing an etiologic role.
2,3 In contrast
with the past, recent reports showing an association
of hypertension and preeclampsia with PPCM are
less frequent.
19
Malnutrition, low socioeconomic status, poor
antenatal care and breast feeding are also
mentioned as risk factors in earlier reports,
1-4,9,22,24
but substantial correlations of these factors have
not been found in further studies.
2,3,5,8,14,23,25,45
There are also reports of other rare risk factors
such as maternal cocaine, alcohol and tobaccoPeripartum Cardiomyopathy
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abuse.
6,9,10,17,35 PPCM also does not have a strong
hereditary association.
3,7,11,17,25 The publications
mentioning these risk factors are several years old
and based on small numbers of patients with older
diagnostic criteria, and so the true association of
these risk factors with PPCM needs serious
reevaluation.
9,35
ETIOLOGY
The actual etiology of PPCM is unknown.
1-3,5,9,
14,17,19-25,29,35,47 Several hypotheses like myocarditis,
viral infection, autoimmune factors, inflammatory
cytokines, abnormal hemodynamic response to
physiological changes in pregnancy, prolonged
tocolysis and selenium deficiency have been
postulated.
1-5,9-11,14,17,21-26,29,48-53
Myocarditis
Myocarditis is defined as dense interstitial as
well as perivascular inflammatory infiltration of
lymphocytes and macrophages in the presence of
myocyte necrosis with or without fibrosis.
25,45
Melvin et al. published the first description of
myocarditis in three patients with PPCM.
46
Reported incidences of myocarditis range between
29 to 100 percent.
8,13,25,45,46,54 Midei et al. reported
a 78% incidence of myocarditis in newly
diagnosed PPCM patients.
25 Recently, idiopathic
dilated cardiomyopathy (IDCM) (9.1%) has also
been reported in PPCM.
10 Ravikishore et al. did
not find any evidence of myocarditis in 12
patients.
38 These discrepancies may be due to
inclusion of patients outside the diagnostic
criteria, problems associated with performance,
timing and interpretation of endomyocardial
biopsies (EMB), variability of histological criteria
and focal changes seen due to vasopressor
therapy.
5,10,11,22,23,25,45 O’Connell et al. suggest that
myocarditis may play an important role in
causation of PPCM early on, and it may be missed
if the biopsy is delayed.
45 Magnetic Resonance
Imaging (MRI)-guided EMB from contrast-enhanced
areas may provide more positive evidence of
acute myocarditis in the early part of the disease.
55
Eosinophils known to have collagenolytic and
cardiotoxic property are found in significant
numbers in PPCM patients.
9 Many such patients
develop myocarditis, implying a role for
eosinophils in the development of myocarditis in
PPCM.
56
Despite such supporting evidence, it has not
been possible to establish a true causal relationship
of myocarditis with PPCM and to delineate
whether it is the cause of PPCM or a different
entity occurring during pregnancy.
14,25
Inflammatory cytokines
Silwa et al., in a large study, found higher
concentrations of inflammatory cytokines like
tumor necrosis factor (TNF ), C-reactive protein α α
(CRP), Interleukin-6 (IL-6) and Fas/Apo-1 (a
marker of apoptosis) in PPCM patients.
30,31 CRP
levels correlated inversely with left ventricular
ejection fraction (LVEF) in their study. High TNF
concentration may lead to advanced ventricular α
remodeling through specific cardiac receptors,
resulting in ventricular dysfunction.
57 Podewski
et al. found a significantly higher level of signal
transducer and activator of transcription-3 against
the myocardium in dead pregnant mice pre-
senting with heart failure and apoptosis.
51
Findings from another murine study indicate that
myocardial apoptosis might have a causative role
in PPCM.
52 Larger studies targeting these
cytokines need to be conducted to establish their
role in PPCM.
Viral infection
Viral infection has also been implicated as a
cause of myocarditis.
6,9,11,14,25,45,46,55,58,59 Depressed
immunity during pregnancy may lead to viral
infection.
5,11,45 Increased susceptibility to viral
myocarditis has been seen in pregnant mice.
3,5,11,
14,45 Bultmann et al. found viral genomic material
in biopsy specimens of PPCM patients.
58 Polymerase
chain reaction (PCR) and extraction of genomic
material from contrast MRI-guided EMB may help
in successful detection of viral genomes.
55 At the
same time, there are several reports without any
prevalence of viral infection in PPCM patients,
2,8,
25,46,48,60 and it has been argued that viral cardio-
myopathy should not be included in PPCM
criteria.
3 Specific further study is essential toPradipta Bhakta, et al.
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establish the relationship of viral myocarditis and
PPCM.
Autoimmune factors
In the 1970s, several reports in support of an
autoimmune nature of PPCM joined reports of
fetal chimerism (presence of fetal cells in maternal
circulation during and after pregnancy).
3,11,25,46,50,61
It has been hypothesized that fetal cells belonging
to the paternal haplotype escape into maternal
circulation due to the depressed immune condition
of pregnancy, and may remain in circulation for
a long time without rejection. Such cells would
be recognized as foreign antigens after normaliza-
tion of maternal immunity following delivery and
may trigger an immune response.
11 McMullan et
al. have proposed that autoantibodies may be
formed against the uterus, placenta or fetus in
pregnant patients.
62 Ansari et al. describe the
presence of higher levels of male chromosomal
DNA in patients with PPCM than in controls.
Smaller concentrations of nonmaternal fetal cells
may aid the viability of the fetus, but higher
levels may trigger autoimmune disease.
50
Development of autoantibodies against smooth
and cardiac muscle has also been reported.
5,50
These autoantibodies may cross react with the
myocardium and can cause cardiomyopathy.
5,25,50,62 The higher rate of PPCM in twin
pregnancies and its familial predisposition also
support this autoimmune theory.
32 Warraich et al.
found markedly increased levels of immunoglo-
bulin (IgG and subclasses) in PPCM patients.
Higher IgG subclass 3 level was seen to be
associated with higher NYHA (New York Heart
Association) class symptomatic presentation.
63
Larger studies are needed to comment on the
definitive role of autoimmunity in PPCM.
8
Abnormal hemodynamic response to physiological
changes in pregnancy
Blood volume and cardiac output (CO) increase,
while systemic vascular resistance (SVR) decreases
in pregnancy.
3,9,14,26,64 Transient left ventricular
dilatation may occur in response to this increased
load.
14 Reduction of left ventricular function in
advanced pregnancy and early puerperium is
typically seen.
64 It has been postulated that PPCM
may be an exacerbation of this normal pheno-
menon.
11
Selenium deficiency
Keshan disease, a form of dilated cardio-
myopathy, has been reported to be associated
with selenium deficiency.
48,65,66 Cenac et al. found
significantly low selenium concentrations in
PPCM patients,
49 which might be a mere incidental
association rather than a cause. Levander stated
that selenium deficiency leads to increased
susceptibility to viral infection, which may in turn
cause cardiomyopathy.
66 Selenium supplementation
has been shown to improve cardiac dysfunction in
chronic tube-fed patients, stressing its importance
in malnourished PPCM patients.
65,67 However,
Fett et al. did not find any such significance of
selenium concentration in PPCM patients.
53
Other factors
Some less important factors which may con-
tribute to the development of PPCM are:
Prolonged tocolytic therapy
17,29,68
However, this treatment may actually unmask
existing heart disease rather than play an etiologic
role.
23,69
Hormones
Relaxin, primarily an ovarian hormone, may
cause excessive cardiac dilatation leading to car-
diomyopathy
23,70 Although previously implicated,
subsequent reports do not support any etiological
role of estrogen, progesterone or prolactin in
PPCM.
3,9,14
Persistent Chlamydia Pneumoni infection
71
Among so many propositions, no study has
clearly delineated any definitive factor(s) respon-
sible for PPCM. Although the etiology is
multifactorial,
9,21,25,65,72 evidence supports myocar-
ditis, inflammatory cytokines and autoimmunity
as the leading mechanisms behind PPCM.
3,5,9,11,
21-23,29,64,69 Rarity and wide geographical variation
make it more difficult to find out the actual cause.Peripartum Cardiomyopathy
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PATHOLOGICAL FEATURES
Heart specimens appear pale, soft, dilated and
heavier in PPCM.
1-3,9,14 Mural thrombi are
invariably seen in one or more cardiac chambers
in patients with persistent ventricular dysfunction.
Gray-white patches of endocardial thickening are
often seen at the sites of mural thrombi.
1-3,9,14
Cardiac valves and coronary vessels appear
normal with the occasional presence of pericardial
effusion.
1,4,9,14 Histological evidence of hypertrophy,
degeneration, fibrosis, interstitial edema, fatty and
mononuclear cell infiltration is seen in the
myocardium with a sparse to abundant collection
of eosinophils.
1-4,8-10,14,45 Electron microscopy has
revealed varying degrees of enlargement, destruc-
tion or fragmentation of myofibrils, an increase in
size and number of mitochondria, glycogen and
some abnormal pertinacious material deposits.
1-3,45,60 Histochemical pictures of myocardial cells
denote occasional sarcoplasmic fat vacuoles
containing triglycerides without any accumulation
of lipofuscin or amyloid.
3 Significantly low levels
of plasma albumin, prealbumin, selenium and
zinc have also been reported.
22,49
CLINICAL PRESENTATION
Symptoms
Dyspnea on exertion, cough, orthopnea and
paroxysmal nocturnal dyspnea are commonly
seen in patients with PPCM and often mimic left
ventricular failure (LVF).
1-3,9,14,17,18,21,22,30,34,36 Cardiac
thrombus formations are not uncommon and they
may present with embolic features like chest pain,
hemoptysis and hemiplegia.
1-3,9,14,17,21-23,27,28,34,35,37
Though extremely rare, single or multiple coronary
embolisms (and myocardial infarctions) have
taken place in patients with PPCM.
73,74 Nonspecific
symptoms like palpitations, fatigue, malaise and
abdominal pain may be present in 50% of cases.
1-4,9,11,14,17,20-22,33 Most PPCM patients present in
NYHA class III or IV,
19-22,25,38 but the use of NYHA
classification may not accurately reflect severity
because of the normal occurrence of these features
in advanced pregnancy.
9,26
Signs
Blood pressure may be normal, elevated or low.
9,14 Tachycardia, gallop rhythm, engorged neck
veins and pedal edema are commonly found
1-4,
9,11,14,17,20-22,33 Clinically, the heart may be normal or
there may be mitral and/or tricuspid regurgita-
tion with pulmonary crepitations and hepato-
megaly.
1-3,11,17,2 Patients may even present with
seizures associated with cerebral edema and
cerebellar herniation.
17,21,39
DIAGNOSIS
Diagnosis of PPCM is based on excluding
common causes of cardiac failure such as infec-
tion, toxins and metabolic, ischemic or valvular
heart disease.
1-3,9,11,14,21,27 Early diagnosis of PPCM
may be difficult because many of the similarities
of its presenting features with that of advanced
pregnancy.
3,9,11,14,22,23,69 Complications of late pre-
gnancy (like anemia, toxemia and amniotic fluid
embolism) have similar manifestations that must
be kept in mind.
9,14 The commonest presentation
of PPCM is in the postpartum period when most
of these features are disappearing.
1,8,9,14,17,29,44
Echocardiography and other laboratory evaluations
strengthen the clinical diagnosis. Common
differential diagnoses include accelerated hyper-
tension, preeclampsia, IDCM, pulmonary embolism,
anemia and thyrotoxicosis, among others.
6,9,14,17,22,69
INVESTIGATIONS
Every patient should have an electrocardiogram
(ECG), chest radiograph (CXR), and Doppler
echocardiograph for diagnosis.
9,22,26
ECG
ECG usually shows sinus tachycardia, though
there may be features of atrial flutter/fibrillation,
left atrial and ventricular hypertrophy (LVH), left
axis deviation, nonspecific ST-T abnormalities,
low voltage complex, arrhythmia, Q wave in
anteroseptal leads and conduction abnormalities
like prolonged PR, QRS intervals and bundlePradipta Bhakta, et al.
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branch blocks.
1-6,9,14,17,22,33,37-39,43,69 The occurrence of
supraventricular/ventricular tachycardia, prema-
ture beats and features of myocardial infarction
are also reported.
1,14,23,39,42,43,45,74,75 The ECG may
even be normal in many cases.
5,14,17,22,45
CXR
There may be evidence of cardiomegaly, LVH,
pulmonary edema, pulmonary venous congestion
and bilateral pleural effusion on CXR,
1,2,7,9,14,17,37,39
or it may be normal.
3
Doppler echocardiography
Doppler echocardiography is the most essential
diagnostic tool for assessing the severity and
gauging the prognosis of PPCM patients.
11,22,69
Common echocardiographic features include
increased left ventricular end diastolic diameter
(LVEDD), decreased left ventricular fractional
shortening (LVFS) and LVEF. Variable systolic
wall thickening, B notch in M mode measurement,
dilatation of all cardiac chambers, mitral,
tricuspid, pulmonary and aortic regurgitation,
diffuse wall motion abnormality and small
pericardial effusions are also reported.
9,11,14,17,20-22,
27,29,32,33,36-42,46,68,69 These regurgitant murmurs are
probably the consequence of cardiac dilatation.
32
Patients with concomitant myocarditis have more
systolic dysfunction than those without
myocarditis.
8 Elevated pulmonary artery pressure
(PAP) and pulmonary arterial hypertension (PAH)
are also seen in the majority of cases.
27,37,42 Some-
times, right ventricular dysfunction and left atrial
enlargement may also be present.
32,42 In a significant
number of cases, cardiac thrombi are found in
different chambers.
14,17,27,30,35 MRI is a more sensitive
tool to diagnose such thrombi than echocardio-
graphy. Echocardiographic measurements have
been used for prognostication of PPCM,
9,11,14,17,19,29,
35,38,45,54 but dobutamine stress echocardiography,
having the capability to show the contractile
reserve, may be a better tool in this regard.
76
Endomyocardial biopsy
The role of routine EMB in PPCM patients is
controversial.
13,25,659,10,17,45,77 The diagnostic sensitivity
of EMB is reported to be 50%, whereas specificity
is very high (99%).
3 EMB has a high rate of false
negativity and results may vary with the timing
of the biopsy. EMB in the early part of the
disease process gives a better positive result.
5,9,25,46 Raised levels of inflammatory cytokines and
lymphocytic myocarditis should be considered
more important than conventional Dallas criteria
for myocarditis. Contrast MRI-guided EMB may
provide more positive results. Interestingly, the
majority of contrast enhancement due to
myocarditis is seen in the lateral wall. PCR and
immunohistological tests of EMB may be more
helpful for detection of inflammation.
55 EMB
always carry some procedural risk, and so it is
best considered if the patient does not improve
even after two weeks of conventional manage-
ment.
2,5,14,23,25,29,59 or there is a strong clinical
suspicion of myocarditis.
73 However, it may be of
value in diagnosis and screening of PPCM
patients scheduled to undergo heart transplant
and those coming for follow up after transplanta-
tion with features of rejection.
13,78
Cardiac catheterization
Cardiac catheterization is used for evaluation of
left ventricular function, obtaining EMB and
performing coronary angiography.
8,9,13,22,27,38 It
reveals elevated cardiac filling pressures and
decreased CO and PAH,
7,13,14,20,22,24,38,45,46 but its
indications are limited to severe heart failure,
abrupt deterioration of symptoms and associated
ischemic heart disease (IHD).
65 Coronary
angiography should always be considered in
patients with positive clinical and ECG features of
IHD, acute coronary syndrome, hyperlipidemia,
history of smoking and diabetes mellitus.
13,22,45,73,74
Other less frequently used investigations
Polymerase chain reaction (PCR)
Used for detection of viral pathology in PPCM
patients who are not improving with conventional
treatment.
21,55
Compliment fixation tests
To detect infection by microorganisms.
2Peripartum Cardiomyopathy
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Blood culture
To rule out any infective cause.
2,9
Radionuclide ventriculography
This method has been used to assess cardiac
function,
8,14,22,25,41,45 but has the drawback of radia-
tion exposure and is superseded by echocardio-
graphy.
12 It may be superior in detecting regional
wall motion abnormalities in IHD patients.
25,45
Immunofluorescence and immunohistochemical staining
Sparsely used for staining of EMB specimens
for detection of autoantibodies against myocar-
dium.
3,22,55
Estimation of cardiac enzymes
Cardiac enzymes are found to be within normal
limits in PPCM and so is coronary angiography.
3,14
Routine hematological, biochemical and serological tests
To rule out other common heart diseases.
2,9,39
Elevated CRP and cytokines suggest inflammatory
cardiomyopathy and their estimation should now be
strongly considered.
30,31,57 The cost-effectiveness of
such tests should be judged on a case to case basis.
PPCM vs. IDCM
PPCM was initially suggested as a variety of
occult IDCM manifesting in late pregnancy.
1,17,22,72
Though PPCM is identical to IDCM in several
ways,
1-3,8,10,38,45 most researchers now accept PPCM
as a distinct entity
1-3,11,43 for the following reasons:
(1) PPCM occurs at a younger age and is gene-
rally associated with better prognosis.
1,2,6,8,13,
27,29,35,43,45,47,54
(2) The incidence of PPCM is higher than IDCM.
10
(3) PPCM occurs mostly postpartum (78 - 93%),
2,6,8,17,19,25,26,29,38,44,63 whereas IDCM usually
manifests by the second trimester.
64,79
(4) PPCM exclusively affects pregnant women
and recurrent PPCM is seen to manifest
again in the peripartum period.
1,72
(5) Varying types of hemodynamic patterns are
seen in PPCM compared to IDCM.
30,34
(6) Unique sets of antigen and antibodies
against myocardium are seen in PPCM
compared to IDCM patients.
11,14,50,63,72
(7) The incidence of myocarditis is higher in
PPCM than in IDCM.
25,45,46
(8) Heart size returns to normal after delivery
in a greater percentage of PPCM patients
compared to IDCM.
1-3,21,25,29,47
(9) Contrary to IDCM, PPCM may lead to rapid
worsening of clinical condition.
8,9,22,45
COMPLICATIONS
Thromboembolism
Thrombi often form in patients with LVEF <
35%
5,21,30,35 and mortality rates of 30 - 50% have
been reported to be due to thromboembolism.
1,9,14,16,22,27,35 Systemic embolism leading to transient
ischemic attack (TIA), hemiplegia, pulmonary
embolism, acute myocardial infarction (AMI),
mesenteric artery occlusion presenting as acute
abdomen, infarction of kidney resulting in
pyelonephritis and splenic infarction have been
reported.
2-4,17-19,21,23,27,28,34,35,37,73,74 Peripheral thrombo-
embolism leading to limb ischemia and gangrene
have also been reported.
21,34
Arrhythmias
Arrhythmias like sinus tachycardia, atrial and
ventricular tachycardia, atrial flutter and fibrilla-
tion, ventricular premature beats, atrial and
ventricular extra systoles and Wolfe-Parkinson-
White Syndrome are reported in PPCM.
2,33,39,42,74,80
Ventricular tachycardia leading to cardiac arrest
has also taken place.
39 Increasing use of automated
implantable cardioverter defibrillators (AICD) in
PPCM patients supports the high risk of life-
threatening arrhythmias.
8,29
Organ failure
Acute liver failure and hepatic coma arising
from passive congestion of cardiac failure in a
PPCM patient have been described.
73 Fatal bacter-
emia and multiorgan failure including the heart,
liver and kidney have also been reported.
29,39
Obstetric & perinatal complications
Increased incidence of abortion (4 - 25%), pre-Pradipta Bhakta, et al.
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mature delivery (11 - 50%), small for date and low
birthweight babies, intrauterine growth retardation
and fetal deaths are reported in PPCM.
14,17,29,44
Congenital fetal anomalies are also described in a
few cases (4 - 6%).
29 Congestive cardiac failure is
associated with higher infant mortality (10%).
3
MANAGEMENT
Medical management of PPCM is similar to that
of heart failure.
1,5,9,21,22,35,65 Fluid and salt restriction,
digoxin, diuretics, vasodilators and anticoagulants
are the mainstays of treatment.
5,9,11,14,17,21-23,26,27,35,65,
81 Safety in pregnancy and lactation should always
be considered before selecting a drug.
11,23
Non-pharmacological measures
Strict bed rest of 6 - 12 months, as had been
advocated previously, is associated with a lower
incidence of cardiomegaly,
24 but the same results
can be achieved without prolonged bed rest.
1 Bed
rest may in fact predispose the patient to deep
venous thrombosis, increasing the risk of sub-
sequent pulmonary embolism.
9 Once incapacitating
symptoms resolve with medical management,
modest exercise may actually improve muscles as
well as arterial tone.
1,11,22,65,82 Salt and fluid intake
should be restricted to 2 - 4 gm/day and 2 L/day,
respectively, and are also important in symptomatic
improvement.
3,5,23,65,81
PHARMACOLOGICAL MANAGEMENT
Digoxin
Digoxin is beneficial for its ionotropic and rate-
reducing effect,
9,21,22 and provides symptomatic
relief without reducing the mortality rate.
81 It is
safe in low doses (higher dose may even increase
inflammatory cytokines) during pregnancy and
lactation and serum digoxin level should be
monitored, particularly when it is co-administered
with diuretics, as pregnant women are unduly
sensitive.
1,3,9,14,21,22,24,82 Continuing digoxin for 6 - 12
months may reduce the risk of recurrence of
PPCM.
14
Diuretics
Diuretics are safe in pregnancy and lactation.
21-23 These are indicated for preload reduction and
symptomatic relief when salt restriction fails.
9,21,22,
69 However, precaution must be taken against
iatrogenic dehydration causing uterine hypoper-
fusion resulting in fetal distress.
5,21-23 A loop
diuretic is commonly used in the hospital setting,
6,36,37,40-42 but thiazides can be used in milder cases.
34,81 Metabolic alkalosis may develop due to
diuretic-induced dehydration. Addition of
acetazolamide will cause reduction of alkalosis by
removing bicarbonate.
81 Spironolactone, probably
due to aldosterone antagonism, has been seen to
reduce symptoms, frequency of hospital admission
and mortality in severe heart failure patients
when used in combination with standard
management.
83 However, spironolactone may not
be safe in pregnancy and is better avoided in the
antepartum period.
65,81
Vasodilators
Because of preload and afterload lowering
effects, vasodilators are vital in heart failure
management. They improve both CO and the
outcome of the failing heart.
5,9,14,22,26,65 Angiotensin
converting enzyme inhibitors (ACEI) or angiotensin
II receptor blockers (ARB) are now considered a
mainstay of management and have been shown to
reduce mortality significantly in heart failure
patients.
5,9,22,23,27,65,82,84 They are contraindicated in
pregnancy due to teratogenicity,
9,21,22,43,65 but should
definitely be considered after delivery, and can
even be considered in advanced pregnancy when
other drugs are ineffective.
22,26 ACEI are excreted
in breast milk and thus breastfeeding should be
discontinued in patients requiring ACEI.
9
Hydralazine with or without nitrates is generally
the vasodilator of choice during pregnancy
5,9,11,
21-23,82 and has been shown to reduce mortality in
the Veterans Administration Heart Failure Trial.
84
Infusion of nitroglycerin and sodium nitroprusside
(SNP) may be needed in severe situations.
5,22,23,32,
36,37,40,41,78 Because of the concern of cyanide
toxicity, SNP may not be a good choice in the
antepartum period.
5,23Peripartum Cardiomyopathy
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Calcium channel blockers
Initially, the use of calcium channel blockers
(CCB) was not acceptable in heart failure because
of their negative contractile effect and the
potential risk of uterine hypoperfusion.
9,11,23,69,85
Amlodipine has now been shown to improve
survival in non-ischemic cardiomyopathy patients.
85 Amlodipine resulted in reduction of IL-6 in the
Prospective Randomized Amlodipine Survival
Evaluation (PRAISE) trial, suggesting a potential
role in PPCM management.
86 Levosimendan, a
calcium sensitizer having vasodilatory properties,
improves cardiac contractility in heart failure
patients.
23,40 Recently, it has been used in a PPCM
patient, successfully causing a steady decline of
elevated pulmonary capillary wedge pressure
(PCWP) and subsequent improvement of CO.
40
Because of the lack of safety reports, breast
feeding should be avoided in patients taking
levosimendan.
23
Beta blockers
Like CCB, earlier beta blockers were also
contraindicated in heart failure. Recent studies
have documented their safety and efficacy in heart
failure patients, though the survival rate is
somewhat confusing.
11,23,65,81 Beta blockers are not
contraindicated in pregnancy, but their use is
associated with low birth weight.
5,23,83 Beta
blockers with additional alpha blocking properties
(example carvedilol) also reduce the afterload.
11 The
reduction of mortality and hospitalization in
chronic heart failure patients has been
documented by the US Carvedilol Heart Failure
Program.
87 Carvedilol has been safely used in
pregnancy and PPCM.
11,30 Beta blockers and ACEI
may play an additional role in suppression of the
immune response,
21 and have also been shown to
prevent remodeling and reduce ventricular
dimensions.
35 There has been no consensus when
to discontinue these primary drugs. Drugs can be
gradually tapered over 6 - 12 months when
ventricular function normalizes clinically and on
echocardiography.
21,35,45,81 If there is evidence of
persistent cardiac dysfunction, associated hyper-
tension or diabetes, drug therapy should be
continued for a long period.
35,65
Antiarrhythmic agents
Antiarrhythmic agents may sometimes be
required to treat symptomatic patients. No antiar-
rhythmic agent is completely safe in pregnancy.
Non-pharmacological means like assurance,
carotid massage or the Valsalva maneuver may
be tried initially.
82 Quinidine and Procainamide
should be tried first because of their higher safety
profile.
82 Treatment should always start in a
hospital setting because of the high incidence of
torsades de pointes associated with their use.
Beta blockers can also be used.
30,82 Digoxin can be
considered for atrial arrhythmias,
69 and adenosine
can also be used in an emergency.
39 Amiodarone
may cause hypothyroidism, growth retardation
and perinatal death, so it should be avoided in
the first trimester and reserved for life threatening
arrhythmias only.
43,69,82 Though primarily indi-
cated in bradyarrhythmia, pacemakers have been
used in PPCM patients for refractory arrhythmias
6,23,29,39,65,82 AICD can be considered in life threa-
tening arrhythmias and has been shown to
reduce the risk of sudden death in PPCM
patients.
11,29,82
Anticoagulant therapy
Patients with an LVEF < 35% and bedridden
patients with atrial fibrillation, mural thrombi,
obesity and a history of thromboembolism benefit
the most from anticoagulant therapy.
1-3,5,9,11,14,17,21,
23,30,35,65 The usual hypercoagulable state of
pregnancy and stasis of blood due to ventricular
dysfunction makes PPCM patients more prone to
thrombus formation and subsequent complica-
tions.
43,88 This situation may persist for as long as
six weeks in the puerperium,
9,35 necessitating the
use of heparin in the antepartum and heparin or
warfarin in the postpartum period.
5,9,14,17,21-23,34,37,65,
69,88 Warfarin is contraindicated in pregnancy for
its teratogenic effect,
89 but the use of both heparin
and warfarin is safe in lactation.
9,23,88
Immunosuppressive therapy
Immunosuppressive therapy with azathioprine
and prednisolone has been tried in myocarditis-
positive PPCM patients.
3,8,25,45,46,59 Melvin et al.Pradipta Bhakta, et al.
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first noted dramatic improvements in three
patients with immunosuppressive therapy.
46 In
another study, 9 of 10 patients showed improve-
ment of PCWP and Left Ventricular Stroke Work
Index (LVSWI) with prednisolone therapy.
25
However, the Myocarditis Treatment Trial failed
to demonstrate any advantage of immunosup-
pressive therapy in PPCM patients.
77 Presently,
there appears to be no indication for routine im-
munosuppressive therapy, but it can be con-
sidered in biopsy-proven PPCM patients who do
not respond to standard medical management
after two weeks.
9,11,14,21-23,25
Immunoglobulin therapy
Human intravenous immunoglobulin (IVIG)
has been shown to improve ventricular dysfunc-
tion in six PPCM patients,
89 although it failed to
show any advantage in IDCM patients.
90 Con-
sidering the increasing evidence of autoimmunity
in PPCM, it may be prudent to consider IVIG in
PPCM patients who do not respond to conven-
tional treatment.
65,89
Interferon
Interferon has been used in biopsy-proven cases
of viral myocarditis, resulting in improvement in
echocardiographic parameters,however, it did not
produce much symptomatic benefit in PPCM
patients.
59
Immunomodulation
Pentoxifylline, an immunomodulating agent
known to reduce production of TNF , CRP and α
Fas/Apo-1, was recently shown to improve
NYHA class, LVEF and outcome in 59 PPCM
patients when combined with conventional
treatment.
30,31 More evidence is required before
pentoxifylline can be recommended.
SURGICAL MANAGEMENT
Cardiac transplant is reserved for those who are
resistant to all medical management.
5,9,11,13,14,17,21-23,
25,39,35,65,91 Success and survival rates are similar to
transplants performed in IDCM patients,
11,17,22 but
the rejection rate is greater due to high titers of
circulating antibodies.
11,17,22,65,91 Patients with
young age, minimal end organ damage and recent
onset PPCM have a more favorable outcome.
9,91,92
Aggressive measures like intra aortic balloon
pumps, ventricular assist devices or cardiopul-
monary or venoatrial bypass may sometimes be
needed as bridging measures until recovery of
cardiac function or definitive cardiac transplant.
5,
35,38,39,65,92,93 Use of these techniques has led to com-
plete recovery and rehabilitation, 93 but these aggres-
sive measures are most useful for healthy young
patients without features of myocarditis.
9,78,92
OBSTETRIC MANAGEMENT
PPCM during the antepartum period demands
intensive fetal and maternal monitoring.
26
Though routinely not required, induction of
delivery should be considered if a patient’s
condition deteriorates despite maximal medical
management.
14,23,26,29,37,65,69,81 A multidisciplinary
approach involving an obstetrician, cardiologist,
anesthesiologist and perinatologist may be
required to provide optimal care to such
patients.
11,14,17,21-23,26, 37,65,69,94 Regional analgesia
reduces the cardiac stress of labor pain,
14,22,26,42,69,95
while application of outlet forceps or a vacuum
device can minimize the cardiac stress of the
second stage of labor.
22,23, 26,64 Cesarean section
has increased risk of blood loss, endometriosis
and pulmonary embolism, and is best done for
obstetric indications as well as in severe
decompensated situations.
5,14,17,22,23,26,29,35-37, 64,69,94
Following delivery, these patients need monitoring
in an Intensive Care Unit (ICU) for early detection
and management of uterine autotransfusion-induced
pulmonary edema.
3,26,41, 64,65,69 Obstetricians should
counsel about breast feeding and future pregnancy
at the time of discharge.
14
Because of the high risk of thromboembolism
with oral contraceptive pills (OCP), barrier con-
traceptive devices are better options for family
planning
1,14,91 Surgical sterilization techniques
like tubal ligation and vasectomy have also been
used.
3,9,26,32Peripartum Cardiomyopathy
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INTENSIVE CARE MANAGEMENT
Patients with severe forms of heart failure may
require more aggressive management in an ICU
with monitoring of arterial blood pressure (ABP),
central venous pressure (CVP), a pulmonary
artery catheter (PAC) and echocardiography
along with inotrope, vasodilator and ventilator
therapy.
11,17,21-23,26,32,36-42,69,75,95 PAC use has a
definite role in the ICU and perioperative
management of severe cases,
6,32,40,41 but its routine
use is associated with many life threatening
complications.
96 Echocardiography is a safer
alternative.
40,79,95 Inotropes like dopamine,
dobutamine and noradrenalin are usually needed
in hypotension.
22,23,26,36,39,40,73 Inodilators such as
amrinone, milrinone, enoximone and levosimendan
may be needed in severe cases with high
afterload.
5,23,35,36,40,69,81 Vasodilatation with nitro-
glycerin, hydralazine or SNP can also be used in
heart failure with high SVR.
23,32,36,37,40,41,69
Levosimendan can be helpful in the weaning of
ionotropes in ionotrope-dependent cases.
23,40
Nesiritide, a brain natriuretic peptide (BNP), has
been shown to reduce elevated PCWP and lead
to clinical improvement, indicating its therapeutic
role in PPCM.
81,97 In extreme situations, multior-
gan support like circulatory assist devices and
continuous veno-venus hemodialysis may be
instituted.
35,37,40,65,93
ANESTHETIC MANAGEMENT
The anesthesiologist plays a vital role in
managing the patients in ICU, providing labor
analgesia, optimizing medical condition of the
mothers for cesarean section and administering
anesthetics for urgent or elective cesarean
section.
PREOPERATIVE OPTIMIZATION
This is mostly similar to ICU management.
Labor analgesia
Single-shot spinal anesthesia is currently not
preferred because of severe consequence like
cardiac arrest and pulmonary edema.
40,41 Con-
trolled epidural analgesia (EA) under invasive
monitoring is a safe and effective method.
17,41
Sympathectomy induced afterload reduction by
controlled regional analgesia has been shown to
improve myocardial function in PPCM patients.
42,69,79,94 Combined spinal-epidural (CSE) analgesia
has the advantages of quick onset of spinal
analgesia with short acting opioids and epidural
catheter-driven prolonged analgesia with low
concentrations of local anesthetics and opioids.
79
Continuous spinal analgesia (CSA) may be the
safest alternative because of greater flexibility,
drug dosage and quality of analgesia.
32,79
Anesthesia for cesarean section
Anesthetic management for cesarean section in
PPCM patients can be challenging to anesthe-
siologists.
35-37 Both general anesthesia (GA) and
regional anesthesia (RA) have been used.
32,36,37,
39-42,75,94-96,98
Regional anaesthesia
Though RA has the advantages of sympathetic
blockade-induced preload and afterload reduc-
tion,
42,69,79,94,95 spinal anesthesia is rarely used
because of complications, as mentioned above.
Graded EA has been mostly used because of its
better hemodynamic stability.
41,42,94,95 CSE, with
its lower failure rates, faster onset, good muscle
relaxation, postoperative analgesia facilities and
better maintenance of hemodynamics has also
been successfully applied.
23,32,42 However, CSE
may cause postdural puncture headache (PDPH),
which can be largely avoided by the use of a
finer gauge pencil point spinal needle.
32,79 CSA
may be considered in severe PPCM cases as it
has the advantages of excellent analgesia, lesser
drug requirement with rapid titrability and
hemodynamic stability.
23,32,42, 79 However, CSA is
associated with a higher incidence of PDPH and
neurological complications, many of which can
be avoided by using a macrocatheter and avoiding
hyperbaric lidocaine.
23,32,79 Recommended pre-
cautions should be taken while using RA in
anticoagulated patients. Infiltration anesthesia
with bilateral ilioinguinal nerve blocks has alsoPradipta Bhakta, et al.
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been used in a severely compromised patient.
98
General anesthesia
GA may be needed in emergency situations or
when RA is contraindicated, particularly in
anticoagulated patients. 36, 37, 41, 69, 75 GA has
the advantages of airway control and ventilation,
and it facilitates the use of transesophageal echo-
cardiography.
42,79 The stress of rapid sequence
induction in compromised cardiac patients can be
dangerous.
42 Both inhalational and intravenous-
based GA have been used in PPCM.
36,37,41,75,96 GA
can cause maternal and fetal cardiorespiratory
depression.
37,41,75 Severe bradycardia leading to
cardiac arrest following institution of GA has
been reported in PPCM patients.
41,75 There is also
increased risk of LVF and pulmonary edema.
41,75
GA does not provide thromboprophylaxis like
RA and carries a high risk of thromboembolism.
37
Opioid-based anesthesia may be advantageous in
compromised cardiac conditions, but carries a
high risk of fetal respiratory depression necessitating
naloxone and artificial ventilation following
childbirth.
36,37,96 Vasodilators may be needed to
accommodate extra blood released by uterine
contraction after delivery.
32 Invasive monitoring
like ABP, CVP and PAC is recommended during
anesthesia in severe cases.
32,36,37,40-42,69,75,79 Nonin-
vasive monitoring has been successfully used in
PPCM.
95
Postoperative management
All PPCM patients should be managed in an
ICU as they are prone to develop LVF and
pulmonary edema in this period, requiring strict
intake/output management.
36,37,39,40,69,75 They may
require vasoactive drugs, mechanical ventilation
and circulatory support at any time.
37,39-41,69,75,79
There is also high risk of thromboembolism,
demanding proper anticoagulation.
37 Postopera-
tive pain can be managed by RA or parenteral
opioid-based techniques.
32,37,40,42,79
Indications for hospital admission
Milder cases can be managed at home, but
moderate to severe cases will require hospital
admission in the following situations:
1. Patients with LVEF less than 35% (because of
high risk of thromboembolism).
65
2. NYHA class III or more symptomatic pre-
sentation (patient may need intensive
management).
11,65
3. Patients presenting with pulmonary edema.
81
4. Thromboembolic complications (increased
possibility of AMI, cerebral or pulmonary
embolism with catastrophic consequences).
65
5. Malignant arrhythmias causing hemodyna-
mic disturbances.
65,81
6. Patients not responding or worsening with
domicile treatment with evidence of vital
organ dysfunction.
65,81
PROGNOSIS
The reported prognosis of PPCM varies in the
literature, but prognosis is currently encouraging
with advanced management.
Recovery from PPCM
Clinical recovery consists of improvements of
symptoms and discontinuation of antifailure
medications.
45 Recovery of ventricular dysfunction
has been defined as (1) LVEF 50% or > 20%
improvement and (2) LVFS 30% in PPCM
patients.
19,35,44 Prognosis is related to left ventri-
cular dysfunction at presentation.
2,9,11 Though
recovery mostly occurs in the first 2 months, it can
take 6 - 12 months.
1,2,19,35 Ninety-one percent of
patients who present with LVEF >30% now recover
in comparison to earlier rates of 50%.
29,27,35,38,43,54
Complete echocardiographic normalization of
cardiomegaly has also been reported.
6,17,35,41,47 A 5-
year survival rate of 94% of patients with
complete recovery of ventricular function has
been reported.
13
Poor prognosis criteria
Generally patients with higher age and parity,
multiple gestations, Black race, later onset (> 2
weeks) of symptoms after delivery, intracardiac
thrombi, cardiac conduction defects, persistence
of ventricular dysfunction six months after
delivery, coexisting medical illness and delay inPeripartum Cardiomyopathy
Yonsei Med J Vol. 48, No. 5, 2007
initiation of medical management have worse
prognosis.
1-3,5,14,27,34,35,38,54 Elderly women ( 35
years) have a 2.8 times greater risk of death. 28
African-Americans experience 6.4 times increased
mortality compared to whites.
28 Higher LVEDD
(> 5.6 cm), PAP and PCWP and reduced LVFS
and LVSWI are usually associated with poor
prognosis.
9,14,17,19,35,38,45,54 Among these, LVEDD
has been reported to be the most important
prognostic indicator.
8,35,45 The combination of
high LVEDD and a left ventricular thrombus is
associated with the worst prognosis.
35 LVEF (<
45%) at two months after diagnosis has also been
found to have poor prognosis.
35 Recently, higher
dilutions of anti-Chlamydial antibody, high TNFα
and IgG class 3 levels have been associated with
poor prognosis.
31,63,71 Compared to postpartum,
antepartum occurrence of PPCM is associated
with poor prognosis in the offspring.
14,46
Mortality
Mortality rates of up to roughly 50% have been
reported in the literature.
1-5,9,11,17,23-29,45,54 Approxi-
mately half die within the first month of
presentation and the majority within the first
three months of postpartum period.
2,19,22,23
However late deaths occurring up to eight years
later, even in the absence of subsequent pregn-
ancy, have also been reported.
1,14,24 The highest
cause of mortality is thromboembolism, as well
as severe congestive heart failure and arrhy-
thmias.
1,2,9,14,19,22,26,65,76 In the USA, pregnancy-
related death due to cardiomyopathy has
increased from 3% in the 1980s to 7.7% in the
1990s.
28 Among all cardiomyopathy-related deaths
in 1991 - 97, 70% were attributed to PPCM.
28 A
maternal death rate of 47.1 per 100,000 births
over 5 years has been reported from Haiti,
compared to that of 0.62 per 100,000 births in the
USA.
19 However, most patients in that Haitian
study did not receive modern heart failure
management. Recently, very low to even zero
mortality has been reported.
13,17,27,29,34,35,44,54 Better
knowledge of pathophysiology, a multimodal
approach and invasive and intensive management
strategies are the cornerstones behind the recent
decrease in mortality.
RISK OF RECURRENCE IN SUBSEQUENT
PREGNANCY
Most reports describe recurrence of PPCM in
subsequent pregnancies.
1-4,9,14,16,21,24,34,44 It is not
clear whether this is due to exacerbation of
previous subclinical failures or reactivation of the
same disease process.
14 The highest risk of
recurrence remains in patients with persistent
cardiac dysfunction and the lowest risk is in those
whose cardiac functions have been normalized, as
evidenced by dobutamine stress test.
1-3,9,13,21-23,43,44,
47,54,76 Multiparity increases the risk of irreversible
cardiac damage in subsequent pregnancies.
11,21,23,
31,65 Recurrence of heart failure ranges between 21-
80% in subsequent pregnancies.
2,3,24,34,43,44 Recently,
a lower recurrence rate was reported with nor-
malization of cardiac function.
13,22,43,47,54 Elkayam
et al. report a more than 20% reduction of LVEF
in subsequent pregnancies in PPCM patients with
prior normalization of cardiac function.
44 Lampert
et al. found that ventricular contractile function is
severely impaired in dobutamine challenge tests
in apparently recovered PPCM patients.
76 Recur-
rence of PPCM has also been reported in patients
whose ventricular size and function have returned
to normal.
2,21,43,99 Even normalization of cardiac
dysfunction does not mean full correction of
PPCM. There usually remains some sort of
residual limitation or ECG abnormalities.
1,2 Con-
sequently, the present criteria used to detect the
recovery of ventricular function based on resting
echocardiography in PPCM patients should be
revised, and the dobutamine stress test may play
a vital role.
14,43,76
AREAS OF FUTURE RESEARCH
There has been wide variation in the incidence
of PPCM worldwide. The actual incidence needs
to be estimated with modified diagnostic criteria,
especially in areas with extremely high incidence.
Older risk factors also need to be reconsidered in
this updated context. Research should be targeted
towards finding the actual etiopathology, with
greater emphasis on inflammatory, viral and
autoimmune causes. The role of EMB in early
resistant cases should be evaluated in large trialsPradipta Bhakta, et al.
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with the help of contrast-enhanced MRI. The
etiologic and diagnostic utility of autoantibodies
and inflammatory cytokines should be studied.
TNF has been recommended as a target for α
future therapeutic options.
57 Therapeutic roles of
immunoglobulin, pentoxifylline, nesiritide and
levosimendan should be evaluated by larger con-
trolled trials. Improvement of ventricular function
and survival has been reported in mice with
reduction in myocardial apoptosis by caspase
inhibition.
52 Caspase inhibition should be evaluated
in PPCM, as myocardial apoptosis may lead to
cardiomyopathy. The current prognosis of PPCM
should be reassessed in the context of modern
management. The role of stress echocardiography
in follow up of PPCM patients with apparent
normalization of cardiac function should be
judged by large controlled trials.
CONCLUSION
PPCM is a rare but devastating cardiac failure
of indeterminate etiology occurring in late pre-
gnancy or early puerperium. Diagnosis of PPCM
should include echocardiographic evidence of left
ventricular dysfunction. Older risk and etiological
factors need current reevaluation in view of
modified diagnostic criteria. The present diagnostic
role of EMB in PPCM is dubious but may be
considered in resistant cases. Routine medical
management should be started with digoxin,
diuretics, vasodilators, blockers and anti β -
coagulants. In resistant cases, treatment with
immunosuppressive drugs, immunoglobulin and
pentoxifylline can be considered. Severe cases may
need intensive management, including mechanical
circulatory support and heart transplant. Induc-
tion of labor should be done in an intensive care
setting. Cesarean section should be reserved for
obstetric indications. Regional techniques are safer
for labor analgesia as well as anesthesia. Invasive
monitoring is recommended in severe cases.
Prognosis is related to recovery of ventricular
dysfunction. Future pregnancy is better avoided
in patients with persistent cardiac failure. If
unavoidable, subsequent pregnancy in patients
with improved cardiac function should be
managed in a multidisciplinary unit.
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